LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
- Your personalised programme is built around medical care, not willpower.
- No generic diets. No guesswork.
- Just science-backed results and expert support.
Find out if you’re eligible
Does Ozempic make you belch? Ozempic (semaglutide) is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes treatment. Belching and flatulence are recognised gastrointestinal side effects of this medication, occurring as part of its broader tolerability profile. These symptoms arise primarily from slowed gastric emptying and altered gut motility. According to the Summary of Product Characteristics, flatulence affects between 1 in 10 and 1 in 100 patients. Understanding these effects and their management is essential for patients and prescribers to optimise treatment outcomes whilst maintaining quality of life.
Quick Answer: Ozempic can cause belching and flatulence as recognised gastrointestinal side effects, with flatulence affecting between 1 in 10 and 1 in 100 patients.
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus. For weight management, the licensed product in the UK is Wegovy (also semaglutide, but at different doses). Gastrointestinal symptoms are well-recognised with this class of medication. Patients frequently report a range of digestive disturbances, including nausea, vomiting, diarrhoea, constipation, and abdominal discomfort.
Belching (eructation) and flatulence can occur as part of the broader spectrum of gastrointestinal side effects associated with Ozempic. The mechanism primarily involves slowing gastric emptying, which can lead to gastric distension and increased belching, particularly of swallowed air. Additionally, the medication's effect on gut motility may alter the normal passage of gas through the digestive tract, with colonic fermentation contributing to flatulence.
According to the electronic Medicines Compendium (emc) Summary of Product Characteristics (SmPC), gastrointestinal disorders are very common with Ozempic, with flatulence specifically listed as a common adverse reaction (affecting between 1 in 10 and 1 in 100 patients). These symptoms are generally considered part of the gastrointestinal tolerability profile of GLP-1 receptor agonists. It is important to distinguish between mild, transient belching and more significant gastrointestinal symptoms that may indicate intolerance or complications requiring medical review.
Of note, semaglutide is not recommended in patients with severe gastrointestinal disease, including severe gastroparesis, as stated in the SmPC.
The precise incidence of belching as an isolated symptom in patients taking Ozempic has been documented in clinical trials. According to the Ozempic SmPC, gastrointestinal adverse effects collectively are very common, affecting more than 1 in 10 patients. The most frequently reported gastrointestinal symptoms include:
Nausea – very common (≥1/10), particularly during dose escalation
Diarrhoea – very common (≥1/10)
Vomiting – common (≥1/100 to <1/10)
Constipation – common (≥1/100 to <1/10)
Abdominal pain and distension – common (≥1/100 to <1/10)
Flatulence – common (≥1/100 to <1/10)
Dyspepsia – common (≥1/100 to <1/10)
The European Medicines Agency's European Public Assessment Report (EPAR) for Ozempic notes that gastrointestinal adverse events are usually mild to moderate in severity and typically occur during dose escalation. Most patients experience these effects transiently, with symptoms generally improving as the body adjusts to the medication.
The severity and duration of gastrointestinal symptoms vary considerably between individuals. Factors that may influence the likelihood of experiencing belching include dietary habits, rate of eating, pre-existing gastrointestinal conditions, and individual sensitivity to changes in gut motility. The incidence of gastrointestinal side effects also tends to increase with higher doses of semaglutide.
LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
Find out if you’re eligible
Dietary and lifestyle modifications can significantly reduce belching and bloating associated with Ozempic. Patients are advised to adopt strategies that minimise gas production and support comfortable digestion:
Eat smaller, more frequent meals rather than large portions, which can overwhelm the already-slowed digestive system
Chew food thoroughly and eat slowly to reduce the amount of air swallowed during meals
Avoid carbonated beverages, which introduce additional gas into the digestive tract
Limit foods known to cause gas, such as beans, lentils, cruciferous vegetables (broccoli, cauliflower, cabbage), onions, and high-fibre foods during the adjustment period
Reduce fatty and fried foods, as these are digested more slowly and may exacerbate symptoms
Stay well hydrated with still water throughout the day to support digestive function and prevent dehydration
Avoid chewing gum and drinking through straws, both of which increase air swallowing
Avoid lying down soon after meals to reduce reflux symptoms
Gradual dose escalation, as recommended in the prescribing information, allows the gastrointestinal system time to adapt to the medication's effects. The standard titration schedule for Ozempic begins at 0.25 mg once weekly for at least four weeks, increasing to 0.5 mg, with further increases to 1 mg or 2 mg if required for glycaemic control, maintaining each dose for at least 4 weeks before increasing.
Some patients find relief with over-the-counter remedies such as simethicone (an anti-foaming agent), though evidence for efficacy in this context is limited. Peppermint preparations should be used with caution as they may worsen reflux symptoms in some individuals. Patients should discuss any additional medications or supplements with their GP or pharmacist to ensure they do not interfere with diabetes management.
Patients taking insulin or sulfonylureas alongside Ozempic should monitor their blood glucose more frequently when experiencing gastrointestinal symptoms that reduce food intake, as there may be an increased risk of hypoglycaemia requiring dose adjustments of these medications.
Whilst mild belching and bloating are generally manageable with lifestyle adjustments, certain symptoms warrant prompt medical review. Patients should contact their GP or diabetes care team if they experience:
Severe or persistent abdominal pain, particularly if localised to the upper abdomen, which may indicate pancreatitis (a rare but serious adverse effect)
Persistent vomiting that prevents adequate fluid or food intake, risking dehydration
Signs of dehydration, including reduced urine output, dizziness, dry mouth, or confusion
Severe diarrhoea lasting more than 48 hours
Unexplained weight loss beyond what is expected from the medication's therapeutic effect
Symptoms of gastroparesis (severe delayed gastric emptying), such as early satiety, persistent nausea, vomiting undigested food, or severe bloating
Right upper quadrant pain, fever, jaundice, pale stools or dark urine, which may indicate gallbladder disease (a known risk with GLP-1 receptor agonists and weight loss)
Markedly reduced urine output, which may indicate acute kidney injury from dehydration
Immediate medical attention (999 or A&E) is required if:
Severe, unrelenting abdominal pain develops, especially if radiating to the back
There is persistent vomiting with inability to keep down fluids
Signs of acute pancreatitis appear (severe upper abdominal pain, fever, rapid pulse)
If pancreatitis is suspected, semaglutide should be stopped immediately and urgent medical assessment sought. If pancreatitis is confirmed, semaglutide should not be restarted.
Patients on insulin or sulfonylureas should contact their diabetes team for advice on dose adjustments if gastrointestinal symptoms are affecting their food intake, to reduce the risk of hypoglycaemia.
Patients should also inform their healthcare provider if gastrointestinal symptoms significantly impair quality of life or adherence to treatment. In some cases, dose adjustment, temporary treatment interruption, or switching to an alternative medication may be appropriate. The decision should be made collaboratively, weighing the benefits of improved glycaemic control against the impact of adverse effects. Regular follow-up, as recommended by NICE guidance for diabetes management (NG28), ensures that any concerns are addressed promptly.
Patients are encouraged to report suspected side effects to the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).
Belching and gastrointestinal symptoms with Ozempic are typically transient, occurring mainly during dose escalation. Most patients find symptoms improve as the body adjusts to the medication over several weeks.
Dietary modifications such as eating smaller meals, avoiding carbonated drinks, and reducing gas-producing foods are first-line approaches. Some patients find relief with simethicone, though you should discuss any additional medications with your GP or pharmacist.
Contact your GP if you experience severe or persistent abdominal pain, persistent vomiting preventing fluid intake, signs of dehydration, or symptoms significantly impairing your quality of life. Severe upper abdominal pain radiating to the back requires immediate medical attention.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
